What TransMedics Group, Inc. does.

We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. We have also developed our NOP, an innovative turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States with a more efficient process to procure donor organs with the OCS. Our transplant logistics services include aviation transportation, ground transportation, and other coordination activity. We believe the use of the OCS combined with the NOP has the potential to significantly increase the number of organ transplants and improve post-transplant outcomes.

Revenue and profit, by fiscal year.

More on TMDX.

• TransMedics Group, Inc. summary
• TransMedics Group, Inc. financial statements
• TransMedics Group, Inc. key metrics
• TransMedics Group, Inc. health scores and style box
• TransMedics Group, Inc. earnings
• TransMedics Group, Inc. dividends
• TransMedics Group, Inc. valuation
• TransMedics Group, Inc. ownership and insiders
• TransMedics Group, Inc. peers

Figures from TransMedics Group, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.